4basebio PLC (FRA:88Q)

Market Cap	94.53M -47.2%
Revenue (ttm)	1.94M +81.5%
Net Income	-19.38M
EPS	-1.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.00
Previous Close	5.90
Day's Range	6.00 - 6.00
52-Week Range	4.70 - 11.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modificatio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 140
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 88Q

Financial Performance

In 2025, 4basebio's revenue was 1.69 million, an increase of 81.46% compared to the previous year's 933,000. Losses were -16.91 million, 37.1% more than in 2024.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error